Loading
Acetazolamide / Heart Failure / Furosemide · Phase 3 Trial
ClinicalTrials.gov · August 17, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 3 multicenter randomized trial evaluating acetazolamide added to standard diuretic therapy in ambulatory heart failure patients during congestive decompensation. No efficacy or safety results are yet available in this registry record; the trial has not yet begun recruitment.
Phase 3, Interventional, Randomized, Parallel, Open label, Treatment purpose. Heart Failure; age from 18 Years. Intervention: Experimental group - Acetazolamide. Compared with: Control group - Standard treatment — Active Comparator. n = 366. 25 sites: France.
This is a planned Phase 3 multicenter randomized trial evaluating acetazolamide added to standard diuretic therapy in ambulatory heart failure patients during congestive decompensation. No efficacy or safety results are yet available in this registry record; the trial has not yet begun recruitment.
No efficacy, safety, or outcome results are reported in this registry record.
The source did not state who this applies to in practice.
This is a Phase 3 trial registration with no reported results; the study is not yet recruiting and outcome data are not posted in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07737964). This is a study registration, not published results. Lead sponsor: University Hospital, Montpellier. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 366 participants (ESTIMATED). Conditions: Heart Failure. Interventions: DRUG: Acetazolamide; DRUG: Furosemide. Primary outcome measures: Percentage of participants with weight loss >2 kg at Day , Day 5. Brief summary: Acute congestion is common in patients with heart failure (HF) and is associated with impaired renal function, reduced quality of life, hospital readmissions, and mortality. Current guidelines recommend optimal decongestion using diuretic therapy, mainly loop diuretics. Although acetazolamide has recently demonstrated efficacy in hospitalized patients, its role in ambulatory patients managed through remote telemonitoring remains to be established. This study aims to evaluate the efficacy of oral acetazolamide added to conventional treatment for decongesting ambulatory HF patients during congestive decompensations. ACHIEVE is a Phase III multicenter, prospective, interventional, randomized, controlled, open-label superiority trial evaluating the efficacy of oral acetazolamide added to conventional treatment for decongestion in ambulatory patients with heart failure during congestive decompensation monitored by remote telemonitoring. The primary objective is to assess, at Day 5, whether acetazolamide added to conventional treatment improves decongestion compared with standard treatment alone. Secondary objectives include evaluating efficacy, safety, and health economic outcomes, including quality of life, dyspnea, biological markers, unplanned consultations, hospitalizations, mortality, and hospital medical costs.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.